G01N 2333/58
Atrial natriuretic factor complex
Official title: Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
G01N2333/58 (Atrial natriuretic factor complex) appears on 158 US grants and 314 published applications in this corpus.
Search patents in G01N- Granted patents
- 158
- Published applications
- 314
- Assignees
- 130
- Inventors
- 543
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 4 |
| 2004 | 1 | 9 |
| 2005 | 0 | 8 |
| 2006 | 0 | 11 |
| 2007 | 2 | 12 |
| 2008 | 5 | 10 |
| 2009 | 6 | 19 |
| 2010 | 8 | 24 |
| 2011 | 13 | 22 |
| 2012 | 9 | 22 |
| 2013 | 16 | 15 |
| 2014 | 7 | 17 |
| 2015 | 13 | 16 |
| 2016 | 6 | 12 |
| 2017 | 7 | 19 |
| 2018 | 9 | 7 |
| 2019 | 4 | 8 |
| 2020 | 7 | 14 |
| 2021 | 8 | 9 |
| 2022 | 5 | 14 |
| 2023 | 6 | 9 |
| 2024 | 6 | 8 |
| 2025 | 9 | 12 |
| 2026 | 4 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating heart failure18 Aug 2026US 12,708,658 B2Zensun (Shanghai) Science & Technology, Co., Ltd.
- Method for selecting a patient for a reperfusion therapy14 Jul 2026US 12,681,022 B2Fundació Hospital Universitari Vall D'Hebron—Institut De Recerca
- Assessing and treating acute decompensated heart failure23 Jun 2026US 12,661,388 B2Mayo Foundation for Medical Education and Research
- Biomarkers for risk prediction of mortality6 Jan 2026US 12,517,139 B2Roche Diagnostics Operations, Inc.
- Methods and compositions involving bucindolol for the treatment of atrial fibrillation9 Dec 2025US 12,491,177 B2Genvara Biopharma, Inc.
- Method for selecting a patient for a reperfusion therapy1 Oct 2026US 2026/0298946 A1Fundació Hospital Universitari Vall D'Hebron—Institut De Recerca
- Protein free solution for stabilizing immunoassay calibrators1 Oct 2026US 2026/0298949 A1Beckman Coulter, Inc.
- Assessing and treating acute decompensated heart failure17 Sep 2026US 2026/0273021 A1Mayo Foundation for Medical Education and Research
- Methods of detecting a disease or condition27 Aug 2026US 2026/0251665 A1Biohabit Ltd
- Effect induced by a sodium-glucose cotransporter inhibitor (sglti) in a subject suffering from a cardiovascular disease13 Aug 2026US 2026/0235623 A1
Most cited
By later US patents
- Diagnostic markers of acute coronary syndrome and methods of use thereof51US 7,361,473 B2Biosite, Inc. · 2008
- Predicting risk of major adverse cardiac events47US 8,090,562 B2Critical Care Diagnostics, Inc. · 2012
- Amelioration of heterophile antibody immunosensor interference42US 8,084,272 B2Abbott Point of Care Inc. · 2011
- Markers for differential diagnosis and methods of use thereof38US 7,713,705 B2Biosite, Inc. · 2010
- Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP33US 7,527,939 B2Nanogen, Inc. · 2009